Keuangan Viking Therapeutics, Inc. (VKTX)
NASDAQ · Healthcare · Biotechnology · Karyawan: 53 · CEO: Brian Lian
- Harga
- $27,28 +1,56%
- Kapitalisasi pasar
- $3,48 M
- Nilai perusahaan
- $3,06 M
- Laporan terakhir
- Q3 '26 diajukan 2026-10-29
- Laporan berikutnya
- 2027-02-10 Estimasi EPS: -$1,38
Pendapatan (TTM)$0– vs tahun lalu4 kuartal terakhir; batang = tiap kuartal
Margin operasional (TTM)–– vs tahun laluLaba operasional: -$649 jt
Laba bersih (TTM)-$627 jt-164,2% vs tahun laluSetelah pajak, termasuk keuntungan non-operasional
Arus kas bebas (TTM)-$463 jt-106,0% vs tahun laluCapex: $0
EPS dilusian (TTM)-$5,40-154,7% vs tahun laluJumlah 4 kuartal terakhir
Kas neto$705 jt-1,2% vs tahun laluKas + investasi jangka pendek - utang
Valuasi & angka utama
- Kapitalisasi pasar
- $3,48 M EV $3,06 M
- Pendapatan
- $0 12 bulan terakhir
- Pertumbuhan pendapatan
- – Konsensus FY2026
- Margin laba
- – Laba bersih / pendapatan, TTM
- P/E
- -5,1× Forward -5,1× (FY2026)
- P/S
- 0,0× Harga / penjualan, TTM
- EV / EBITDA
- -4,9× TTM
- Arus kas bebas
- -$463 jt 12 bulan terakhir
- Laba bersih
- -$627 jt 12 bulan terakhir
- Estimasi pendapatan
- $7,17 jt Konsensus FY2026
- Laba
- 2027-02-10
- Dividen
- – Tanpa dividen
Poin-poin utama
Dihitung dari angka yang dilaporkan - setiap pernyataan menyertakan angka yang mendasarinya.
- Laporan terakhir (2026-10-28): pendapatan n/a, EPS meleset 46,2%Pendapatan – vs – yang diharapkan (–); EPS -$1,55 vs -$1,06 (-46,2%).
- Jumlah saham dilusian naik dalam setahun: 5,1%Saham dilusian pada Q3 '26: 118 jt, setahun sebelumnya: 112 jt.
- Kas neto: $705 jtKas + investasi jangka pendek: $960 jt, utang termasuk sewa: $255 jt; tahun lalu kas neto: $714 jt.
Kuartal terakhir: Q3 '26
Kuartal berakhir 2026-09-30. Dibandingkan dengan kuartal yang sama tahun lalu dan konsensus analis sebelum laporan.
Kuartal vs tahun lalu
| Q3 '26 | Tahun lalu | Perubahan | |
|---|---|---|---|
| Pendapatan | $0 | $0 | – |
| Laba operasional | -$187 jt | -$98,6 jt | -89,8% |
| Laba bersih | -$183 jt | -$90,8 jt | -101,8% |
| EPS dilusian | -$1,55 | -$0,81 | -91,4% |
| Arus kas operasional | -$138 jt | -$94 jt | -47,0% |
| Capex | $0 | $0 | – |
| Arus kas bebas | -$138 jt | -$94 jt | -47,0% |
| R&D | $167 jt | $90 jt | +85,4% |
| Kompensasi berbasis saham | $17,9 jt | $7,34 jt | +143,9% |
Dilaporkan vs konsensus
2026-10-28| Aktual | Konsensus | vs konsensus | |
|---|---|---|---|
| EPS (basis konsensus) | -$1,55 | -$1,06 | -46,2% |
Dari laporan 2026-10-28 untuk Q3 '26: pendapatan dan EPS yang diperkirakan analis (sering disesuaikan), sehingga bisa berbeda dari EPS laporan keuangan di atas.
EPS vs konsensus
8 laporan terakhirPendapatan
Dari mana uang berasal - menurut lini bisnis dan wilayah, kuartal demi kuartal.
Pendapatan, laba operasional, dan pertumbuhan
kuartalanMargin & struktur biaya
Berapa bagian dari setiap unit pendapatan yang tersisa di tiap tingkat - dan ke mana biaya mengalir.
Margin
kuartalanBiaya sebagai % pendapatan
kuartalanArus kas & alokasi modal
Kas yang dihasilkan, untuk apa kas itu digunakan, dan apa yang sampai ke pemegang saham.
Arus kas operasional, capex, arus kas bebas
kuartalanPenggunaan kas vs arus kas operasional
tahun fiskal4 kuartal terakhir
laporan arus kas- Arus kas operasional
- -$463 jt
- Capex
- $0
- Buyback
- $0
- Dividen
- $0
- Akuisisi
- $0
- Utang neto diterbitkan
- $251 jt
- Kompensasi berbasis saham
- $47,9 jt
- Arus kas bebas
- -$463 jt
- Dikembalikan ke pemegang saham / FCF
- 0,0%
Jumlah saham dan EPS
kuartalan, dilusianNeraca
Likuiditas, investasi, dan utang pada akhir setiap kuartal.
Kas, investasi, dan utang
akhir kuartalValuasi & imbal hasil
Multiple saat ini dibandingkan lima tahun fiskal terakhir perusahaan itu sendiri; target dan peringkat analis.
Multiple dan imbal hasil
TTM vs 5 tahun fiskal| Sekarang | Rata-rata 5 th | Posisi saat ini dalam rentang 5 tahun | |
|---|---|---|---|
| P/E (TTM) | -5,1× | – | – |
| EV / EBITDA | -4,9× | – | – |
| EV / Penjualan | 0,0× | – | – |
| Harga / FCF | -7,5× | – | – |
| Harga / Nilai buku | 5,5× | 4,6× | 1,8× – 6,2× |
| Imbal hasil FCF | -13,3% | -6,7% | -13,4% – -2,0% |
| Imbal hasil modal yang diinvestasikan | -76,9% | -36,6% | -61,5% – -17,1% |
| Imbal hasil ekuitas | -117,3% | -33,6% | -56,3% – -12,5% |
Analis
Target konsensus $82,00 (+200,6%)
rentang $34,00 – $120,00 · peringkat Buy
Beli kuat1
Beli22
Tahan1
Jual0
Jual kuat0
Prospek
Konsensus analis untuk tahun fiskal mendatang dan implikasinya pada harga saat ini.
Estimasi konsensus
| Tahun fiskal | Pendapatan | Pertumbuhan | EPS | Pertumbuhan | P/E pada harga saat ini | Analis (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $7,17 jt | – | -$5,32 | -66,7% | -5,1× | 13 |
| FY2027 | $7,35 jt | +2,5% | -$5,15 | +3,2% | -5,3× | 15 |
| FY2028 | $217 jt | +2.854,9% | -$3,93 | +23,6% | -6,9× | 15 |
| FY2029 | $483 jt | +122,2% | -$1,69 | +57,0% | -16,1× | 9 |
| FY2030 | $1,15 M | +138,2% | $1,66 | +198,4% | 16,4× | 6 |
Laporan keuangan
Setiap baris laporan laba rugi, neraca, dan laporan arus kas - 12 kuartal dan 10 tahun fiskal, sebagai nilai, % pendapatan, atau pertumbuhan.
Semua pos yang dilaporkan
Semua 161 angka yang ditandai Viking Therapeutics, Inc. dalam laporan 10-Q / 10-K terbarunya, dengan label dan definisi resmi SEC - termasuk catatan (sewa, pajak, buyback, karyawan, ...).
| Pos (label SEC) | Kuartal terakhir | Tahun lalu | yoy | FY terakhir | FY sebelumnya | yoy |
|---|---|---|---|---|---|---|
| $88 rb | $0 | – | – | – | – | |
| Accounts Payable, Current | $82,1 jt | $4,41 jt | +1.761,2% | $53,3 jt | $9,81 jt | +442,7% |
| Accretion (Amortization) of Discounts and Premiums, Investments | $796 rb | $2,03 jt | -60,8% | $9,28 jt | $17,3 jt | -46,2% |
| Additional Paid in Capital, Common Stock | $1,91 M | $1,4 M | +36,0% | $1,49 M | $1,37 M | +8,6% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 4,82 jt | -149 rb | +3.322,7% | 7,35 jt | 7,45 jt | -1,4% |
| AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax | -$1,7 jt | $374 rb | -554,0% | $378 rb | -$788 rb | +148,0% |
| APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition | $17,9 jt | $7,34 jt | +143,9% | $40,8 jt | $29,7 jt | +37,4% |
| Assets | $977 jt | $739 jt | +32,2% | $716 jt | $908 jt | -21,2% |
| Assets, Current | $973 jt | $739 jt | +31,7% | $716 jt | $907 jt | -21,1% |
| Assets, Fair Value Disclosure | $836 jt | $683 jt | +22,3% | $599 jt | $895 jt | -33,0% |
| Cash and Cash Equivalents, at Carrying Value | $678 jt | $100 jt | +575,1% | $166 jt | $26,7 jt | +521,6% |
| Cash and Cash Equivalents, Fair Value Disclosure | $553 jt | $68,8 jt | +703,7% | $59,1 jt | $18,6 jt | +218,0% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | $678 jt | $100 jt | +575,3% | $166 jt | $26,7 jt | +521,6% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect | $552 jt | $66,5 jt | +729,9% | $139 jt | -$28,7 jt | +585,0% |
| Common Stock, Capital Shares Reserved for Future Issuance | 23,6 jt2025-12-31 | 24,7 jt | -4,4% | 23,6 jt | 24,7 jt | -4,4% |
| Common Stock, Par or Stated Value Per Share | $0,00 | $0,00 | 0,0% | $0,00 | $0,00 | 0,0% |
| Common Stock, Shares Authorized | 300 jt | 300 jt | 0,0% | 300 jt | 300 jt | 0,0% |
| Common Stock, Shares, Issued | 128 jt | 112 jt | +13,4% | 115 jt | 112 jt | +2,9% |
| Common Stock, Shares, Outstanding | 128 jt | 112 jt | +13,4% | 115 jt | 112 jt | +2,9% |
| Common Stock, Value, Issued | $1 rb | $1 rb | 0,0% | $1 rb | $1 rb | 0,0% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$184 jt | -$90,2 jt | -103,6% | -$358 jt | -$110 jt | -224,8% |
| Convertible Notes Payable, Noncurrent | $251 jt | – | – | $2,15 jt2015-12-31 | $1,26 jt | +70,2% |
| Current Federal Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Current Federal, State and Local, Tax Expense (Benefit) | – | – | – | $1 rb | $1 rb | 0,0% |
| Current State and Local Tax Expense (Benefit) | – | – | – | $1 rb | $1 rb | 0,0% |
| Debt Securities, Available-for-sale | $282 jt | $614 jt | -54,1% | $540 jt | $876 jt | -38,4% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $1 rb | $1,01 jt | -99,9% | $932 rb | $802 rb | +16,2% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $1,22 jt | $144 rb | +750,0% | $88 rb | $1,08 jt | -91,8% |
| Debt Securities, Available-for-sale, Amortized Cost | $283 jt | $613 jt | -53,8% | $539 jt | $876 jt | -38,5% |
| Debt Securities, Available-for-sale, Current | $282 jt | $614 jt | -54,1% | $540 jt | $876 jt | -38,4% |
| Debt Securities, Available-for-sale, Gain (Loss) | $02026-03-31 | – | – | – | – | – |
| Debt Securities, Available-for-sale, Realized Gain (Loss) | – | – | – | $10 rb | – | – |
| Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions | 113 Security | 82 Security | +37,8% | 59 Security | 132 Security | -55,3% |
| Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance | – | – | – | 1 jt2014-02-28 | – | – |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | -$60,4 jt | -$33,2 jt | -81,9% |
| Deferred Federal, State and Local, Tax Expense (Benefit) | – | – | – | -$101 jt | -$45,1 jt | -123,2% |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | -$19,6 jt | $0 | – |
| Deferred State and Local Income Tax Expense (Benefit) | – | – | – | -$20,8 jt | -$11,9 jt | -74,0% |
| Deferred Tax Assets, Goodwill and Intangible Assets | $134 jt2025-12-31 | $93,1 jt | +44,1% | $134 jt | $93,1 jt | +44,1% |
| Deferred Tax Assets, Gross | $265 jt2025-12-31 | $164 jt | +61,2% | $265 jt | $164 jt | +61,2% |
| Deferred Tax Assets, Net | $02025-12-31 | $0 | – | $0 | $0 | – |
| Deferred Tax Assets, Net of Valuation Allowance | $247 rb2025-12-31 | $281 rb | -12,1% | $247 rb | $281 rb | -12,1% |
| Deferred Tax Assets, Operating Loss Carryforwards | $68,2 jt2025-12-31 | $40,8 jt | +67,1% | $68,2 jt | $40,8 jt | +67,1% |
| Deferred Tax Assets, Operating Loss Carryforwards, Domestic | $195 jt2025-12-31 | $158 jt | +23,4% | $195 jt | $158 jt | +23,4% |
| Deferred Tax Assets, Operating Loss Carryforwards, Foreign | $156 jt2025-12-31 | – | – | $156 jt | – | – |
| Deferred Tax Assets, Operating Loss Carryforwards, State and Local | $111 jt2025-12-31 | $110 jt | +0,9% | $111 jt | $110 jt | +0,9% |
| Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration | $17,7 jt2025-12-31 | $17,8 jt | -0,6% | $17,7 jt | $17,8 jt | -0,6% |
| Deferred Tax Assets, Other | $02025-12-31 | $91 rb | -100,0% | $0 | $91 rb | -100,0% |
| Deferred Tax Assets, Tax Credit Carryforwards, Research | $58,3 jt2025-12-31 | $27,2 jt | +114,2% | $58,3 jt | $27,2 jt | +114,2% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | $4,24 jt2025-12-31 | $2,8 jt | +51,5% | $4,24 jt | $2,8 jt | +51,5% |
| Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities | $174 rb2025-12-31 | $403 rb | -56,8% | $174 rb | $403 rb | -56,8% |
| Deferred Tax Assets, Valuation Allowance | $265 jt2025-12-31 | $164 jt | +61,4% | $265 jt | $164 jt | +61,4% |
| Deferred Tax Liabilities, Net | $247 rb2025-12-31 | $281 rb | -12,1% | $247 rb | $281 rb | -12,1% |
| Deferred Tax Liabilities, Other | $223 rb2025-12-31 | $0 | – | $223 rb | $0 | – |
| Deposits Assets, Noncurrent | $113 rb | $46 rb | +145,7% | $46 rb | $46 rb | 0,0% |
| Earnings Per Share, Basic | -$1,55 | -$0,81 | -91,4% | -$3,19 | -$1,01 | -215,8% |
| Earnings Per Share, Diluted | -$1,55 | -$0,81 | -91,4% | -$3,19 | -$1,01 | -215,8% |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | -$26 rb | -$6 rb | -333,3% | -$8 rb | -$148 rb | +94,6% |
| Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | – | – | – | -$75,5 jt | – | – |
| Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | – | – | – | 21,0% | 21,0% | 0,0% |
Sumber: SEC companyfacts (XBRL setiap 10-Q / 10-K). Kuartal arus kas dihitung dari angka kumulatif tahun berjalan yang ditandai dalam 10-Q. Rincian segmen ditandai dengan dimensi dan ditampilkan di bagian segmen.
Sumber
Laporan keuangan, pendapatan segmen, metrik, dan estimasi distandardisasi dari laporan perusahaan. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30
Data per 2026-11-02